Chronic Pancreatitis (Investigational Pain Adjunct)

Highly investigational adjunct for chronic pancreatitis pain refractory to conventional therapy; case reports only; pancreatic enzyme replacement and pain medicine remain primary.

Tier C — InvestigationalInvestigationalLast Updated: May 26, 2026 · Reviewed by: ASH Editorial Board

Patient Summary

Is this FDA-cleared for this use?: Not FDA-cleared for chronic pancreatitis pain. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?: Tier C (investigational). No controlled trials in chronic pancreatitis. Evidence-based first-line pain management is alcohol cessation, smoking cessation (the strongest disease modifiers), pancreatic enzyme replacement for steatorrhea, non-opioid analgesics, pregabalin or amitriptyline for neuropathic pain, and for refractory cases endoscopic decompression, celiac plexus block, or total pancreatectomy with islet auto-transplantation.
Main risks: Bleeding from each bite site for 6 to 10 hours after the leech detaches
Iron-deficiency anemia from cumulative blood loss across multiple sessions
Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
Local pain, bruising, swelling, or itching for 1 to 3 days after each session
Misleading pain reduction that delays needed work-up for complications such as pseudocyst, pancreatic cancer, or duct stricture
Who should not consider this: Patients still using alcohol or tobacco (these are the strongest disease modifiers)
Patients with new red-flag symptoms (weight loss, jaundice, GI bleeding) requiring urgent oncology workup
Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
People with hemophilia or any other inherited bleeding disorder
Patients with severe anemia (hemoglobin under 10 g/dL)
People with an active infection at the planned application site
Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
What to ask your clinician: Have I been fully evaluated for treatable structural causes (duct stricture, stone, pseudocyst)?
Have I been screened for pancreatic cancer given my chronic pancreatitis (it is a known risk factor)?
Am I on optimal enzyme replacement and neuropathic-pain medications?
Has celiac plexus block, endoscopic decompression, or surgical options been discussed?
What is the published evidence base for leeches in chronic pancreatitis pain?
How will worsening of structural disease be detected during the leech course?
When to seek urgent care: Bleeding from a bite site that soaks through more than one dressing per hour
Bleeding that continues more than 24 hours after the leech detached
Spreading redness, warmth, swelling, pus, or red streaks around any bite site
Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
New or worsening abdominal pain radiating to the back, with vomiting or fever (possible acute pancreatitis flare)
New jaundice, dark urine, pale stools, or unexplained weight loss (possible cancer)
GI bleeding (vomiting blood or black stools)

What this does NOT mean

It does not mean leech therapy is FDA-cleared for chronic pancreatitis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
It does not replace alcohol and smoking cessation, the strongest disease modifiers.
It does not change the underlying pancreatic fibrosis and inflammation.
It does not address pancreatic exocrine or endocrine insufficiency.
It does not have controlled-trial evidence and may mask warning signs of pancreatic cancer or complications.

Safety cross-references

Clinical Profile

Category: Gastrointestinal
ICD-10: K86.1, K86.0
Safety tier: High

Evidence Summary

Chronic pancreatitis management per ACG guidance (Gardner et al. 2020) includes smoking and alcohol cessation, pancreatic enzyme replacement therapy for exocrine insufficiency, glycemic control for endocrine insufficiency, multimodal pain management (acetaminophen, gabapentin, opioid-sparing strategies), endoscopic intervention for ductal disease, and total pancreatectomy with islet auto-transplant in highly selected refractory cases. No controlled clinical trial of leech therapy for chronic pancreatitis has been published; use is investigational and mechanistic only, and the honest evidence grade is D. Any antiinflammatory or neuropathic-pain rationale for paraspinal application is theoretical, with substantial concern about masking acute pancreatitis flares or pancreatic cancer pain.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Acute pancreatitis or recent flare (<8 weeks)
Suspected pancreatic cancer
Active alcohol use disorder requiring stabilization
Severe malnutrition (BMI <18.5)
Coagulopathy from advanced pancreatic insufficiency

Related Conditions

Hemorrhoids (Grade II-III, Symptomatic)

Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.

External Thrombosed Hemorrhoid (Acute, <72h)

Investigational adjunct for acute external thrombosed hemorrhoids presenting within 72 hours; distinct from internal hemorrhoidal disease.

Chronic Anal Fissure (>8 Weeks)

Investigational adjunct for chronic anal fissure refractory to medical therapy; very limited case-report evidence; surgical sphincterotomy remains gold standard.

Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)

Investigational adjunct in NAFLD/MASLD; small case series only; weight loss, dietary modification, and resmetirom remain primary.